Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg
Arrotex Pharmaceuticals Pty Ltd
pramipexole dihydrochloride monohydrate
Tablet, uncoated
Excipient Ingredients: mannitol; magnesium stearate; silicon dioxide; pregelatinised maize starch; povidone
Oral
10, 30, 100
(S4) Prescription Only Medicine
Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.,-the symptomatic treatment of primary Restless Legs Syndrome.
Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2014-09-23